Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.

@article{Glintborg2013ClinicalRD,
  title={Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.},
  author={Bente Glintborg and Mikkel Ostergaard and Niels Steen Krogh and Martin Andersen and Ulrik Tarp and Anne Loft and Hanne Merete Lindegaard and Mette Holland-Fischer and Henrik Nordin and Dorte Vendelbo Jensen and Christian Holkmann Olsen and Merete Lund Hetland},
  journal={Arthritis and rheumatism},
  year={2013},
  volume={65 5},
  pages={1213-23}
}
OBJECTIVE To describe the frequency of treatment switching and outcomes among patients with psoriatic arthritis (PsA) who switched tumor necrosis factor α inhibitor (TNFi) agents in routine care. METHODS We conducted an observational cohort study based on the Danish nationwide DANBIO registry. Treatment outcomes were evaluated using the American College of Rheumatology criteria for 20% improvement (ACR20)/ACR50/ACR70, European League Against Rheumatism (EULAR) response criteria for good… CONTINUE READING